Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
3.700
-0.310 (-7.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
22
23
Next >
Investor Sentiment Edges Lower; Dow Jumps Over 100 Points
↗
December 28, 2023
The CNN Money Fear and Greed index showed a decline in overall market sentiment, but the index remained in the "Extreme Greed" zone on Wednesday. U.S. stocks closed higher on Wednesday, with the Dow...
Via
Benzinga
Topics
Stocks
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
↗
December 27, 2023
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.05% to 37,564.54 while the NASDAQ fell 0.04% to 15,069.30. The...
Via
Benzinga
Topics
Stocks
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
December 27, 2023
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per...
Via
Benzinga
Why Iovance Biotherapeutics Stock Is Crashing Today
↗
December 27, 2023
One of the small biotech's top pipeline programs ran into a major setback.
Via
The Motley Fool
Why Iovance Biotherapeutics Stock Is Jumping Today
↗
November 20, 2023
Another Wall Street analyst has jumped aboard the Iovance train.
Via
The Motley Fool
Why Iovance Biotherapeutics Stock Is Marching Higher Today
↗
November 08, 2023
Investors are excited by the prospects of a potential regulatory approval.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
↗
December 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
December 27, 2023
Via
Benzinga
Gold Gains 1%; Richmond Fed Manufacturing Index Falls In December
↗
December 27, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626.76 while the NASDAQ rose 0.06% to 15,084.02. The S&P...
Via
Benzinga
Topics
Economy
Stocks
Iovance Biotherapeutics, Nio, NetEase And Other Big Stocks Moving Lower On Wednesday
↗
December 27, 2023
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday.
Via
Benzinga
Topics
Stocks
Analyst Expectations for Iovance Biotherapeutics's Future
↗
November 08, 2023
Via
Benzinga
Earnings Preview: Iovance Biotherapeutics
↗
November 06, 2023
Via
Benzinga
FDA Slaps Clinical Hold On Iovance Biotherapeutics' Lung Cancer Study After Patient Death
↗
December 27, 2023
Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-
Via
Benzinga
US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY
↗
December 27, 2023
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
December 27, 2023
Via
Benzinga
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
December 27, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
↗
December 12, 2023
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.
Via
The Motley Fool
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
↗
December 12, 2023
There's a huge gap between what the stock market and Wall Street analysts have to say about this often-overlooked growth stock.
Via
The Motley Fool
Crude Oil Gains Over 2%; PaxMedica Shares Plunge
↗
November 20, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Monday. The Dow traded up 0.34% to 35,064.42 while the NASDAQ rose 0.80% to 14,238.67. The S&P 500...
Via
Benzinga
Topics
Stocks
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 20, 2023
Shares of ReNew Energy Global Plc (NASDAQ: RNW) gained during Monday’s session following strong quarterly sales. ReNew Energy Global posted quarterly sales of $345.00 million, topping market estimates...
Via
Benzinga
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 17, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
↗
November 08, 2023
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.
Via
Benzinga
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 20, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
October 19, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
October 16, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.